Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (61-70 of 191) with videos related to

Pageof 20
Sort By:
AIDS (London, England)|December 28, 2017
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphomaPaul G Rubinstein, Page C Moore, Michelle A Rudek, et al.
JAMA Network Open|December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical TrialsJoshua E Reuss, Diana Stern, Jared C Foster, et al.
JCO Global Oncology|May 2, 2024
Perspective: The COVID-19 Pandemic: Closing Borders, Opening Doors, and Breaking Ground on the Potential for Clinical Trial Access in Developing Countries Like Trinidad and TobagoKellie Alleyne-Mike, John Glod, Erissa Cuffie, et al.
AIDS Reviews|October 26, 2020
Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan AfricaJonathan D Strope, Sarah E Lochrin, Tristan M Sissung, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Cancers|January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) TrialErel Joffe, Anita Kumar, Joseph M Tuscano, et al.
JAMA Oncology|December 26, 2025
Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 AgentsZoe E Quandt, Shanda Finnigan, Vanessa Hill, et al.
NPJ Precision Oncology|June 12, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitorsHarold Nathan Tan, Hung Le, Khaoula Ben Haj Frej, et al.
Science Translational Medicine|October 25, 2013
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppressionRaffit Hassan, Andrew C Miller, Elad Sharon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer StatementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Pageof 20

Showing results (61-70 of 191) with videos related to

Sort By:
Pageof 20
AIDS (London, England)|December 28, 2017
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphomaPaul G Rubinstein, Page C Moore, Michelle A Rudek, et al.
JAMA Network Open|December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical TrialsJoshua E Reuss, Diana Stern, Jared C Foster, et al.
JCO Global Oncology|May 2, 2024
Perspective: The COVID-19 Pandemic: Closing Borders, Opening Doors, and Breaking Ground on the Potential for Clinical Trial Access in Developing Countries Like Trinidad and TobagoKellie Alleyne-Mike, John Glod, Erissa Cuffie, et al.
AIDS Reviews|October 26, 2020
Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan AfricaJonathan D Strope, Sarah E Lochrin, Tristan M Sissung, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Cancers|January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) TrialErel Joffe, Anita Kumar, Joseph M Tuscano, et al.
JAMA Oncology|December 26, 2025
Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 AgentsZoe E Quandt, Shanda Finnigan, Vanessa Hill, et al.
NPJ Precision Oncology|June 12, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitorsHarold Nathan Tan, Hung Le, Khaoula Ben Haj Frej, et al.
Science Translational Medicine|October 25, 2013
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppressionRaffit Hassan, Andrew C Miller, Elad Sharon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer StatementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Pageof 20